Health care systems as determinants of outcomes in multiple myeloma: final results from the Latin American MYLACRE study
Authors:
- Vania HungriaVHVania Hungria
- Rafael GaiollaRGRafael Gaiolla
- Kenny GalvezKGKenny Galvez
- Guillermina RemaggiGRGuillermina Remaggi
- Natalia SchutzNSNatalia Schutz
- Angelo MaiolinoAMAngelo Maiolino
- Guillermo Quintero-VegaGQGuillermo Quintero-Vega
- Carolina Colaco VillarimCVCarolina Colaco Villarim
- Edvan CrusoeECEdvan Crusoe
Open Access
- 13 March 2025
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (6) , 1293-1302
Abstract
Although systemic therapy for multiple myeloma (MM) has evolved considerably over the past 2 decades, state-of-the-art treatment is not uniformly available in Latin America. In some countries, disparities between the public and private sectors in clinical presentation, access to novel agents, and transplantation are striking, with the public sector lagging. We conducted a multicenter, observational study of patients with MM in 5 Latin American countries (Argentina, Brazil, Colombia, Mexico, and Panama). We enrolled patients aged ≥18 years diagnosed with MM between January 2016 and June 2021, using data collected between May 2019 and June 2022. We categorized institutions as “public” when primarily funded by federal or local government, and “private” when financed mostly or completely by other sources. We analyzed 1029 patients, 1021 of whom could be classified into public (n = 339) and private (n = 682) institutions. These 2 groups differed in many respects, with patients from the latter having better baseline prognostic features (including eligibility to transplantation) and receiving combinations of immunomodulatory drugs and proteasome inhibitors, as well as anti-CD38 antibodies, more frequently than patients from public institutions. Among 960 patients with complete data for this analysis, the median overall survival was 44.6 months in public institutions and 53.3 months in private institutions (hazard ratio, 0.84; 95% confidence interval, 0.67-1.04; P = .109). Our results indicate diagnostic and therapeutic shortcomings in the management of MM in Latin America, with important gaps in patient profile, treatment patterns and long-term outcomes between public and private institutions. This trial was registered at www.clinicaltrials.gov as #NCT03955900.Keywords
This publication has 40 references indexed in Scilit:
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaNew England Journal of Medicine, 2018
- Observational study of multiple myeloma in Latin AmericaAnnals of Hematology, 2016
- Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional studySao Paulo Medical Journal, 2016
- International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology, 2014
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with MyelomaNew England Journal of Medicine, 2014
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple MyelomaNew England Journal of Medicine, 2012
- Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myelomaHaematologica, 2008
- Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trialThe Lancet, 2007
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 2006
- Median follow-up in clinical trials.Journal of Clinical Oncology, 1991